Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Exenatide

Knowing that you are interested in Exenatide, we have listed articles on similar topics on the website for your convenience. As a professional manufacturer, we hope that this news can help you. If you are interested in learning more about the product, please feel free to contact us.
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 4 2024

    2024-11-04

    This week, there are 11 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's XIIDRA, containing active ingredient LIFITEGRAST - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - MYLAN SPECIALTY LP's TOBI PODHALER, containing active ingredient TOBRAMYCIN - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - ASTRAZENECA AB's BYETTA, containing active ingredient EXENATIDE SYNTHETIC - HOFFMANN-LA ROCHE INC's ALECENSA, containing active ingredient ALECTINIB HYDROCHLORIDE - HOFFMANN LA ROCHE INC's ZELBORAF, containing active ingredient VEMURAFENIB - GISKIT PHARMA BV's EXEM FOAM KIT, containing active ingredient AIR POLYMER-TYPE A - MERCK SHARP AND DOHME CORP's PREVYMIS, containing active ingredient LETERMOVIR - MERCK SHARP AND DOHME LLC's PREVYMIS, containing active ingredient LETERMOVIR - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB Read More